Drug intelligence / Profile preview

Mynosit

Development stage: Unknown
Lead developer: Zealina Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

**Mynosit** is a marketed oral fixed-dose tablet from Zealina Life Sciences containing myo-inositol 1 g, levomefolate calcium 500 mcg, cholecalciferol 1,000 IU, and melatonin 1.5 mg. It is marketed as a prescription nutritional-support product for nutritional deficiencies, with retail medicine references also listing vitamin D deficiency and insomnia. Its component pharmacology includes vitamin D receptor activation by cholecalciferol and melatonin receptor agonism by melatonin; myo-inositol and levomefolate calcium provide metabolic and folate nutritional support. ([1mg.com](https://www.1mg.com/drugs/mynosit-tablet-636483))

Brand names: Mynosit
Other names: myo-inositol + l-methylfolate calcium + vitamin d3 + melatonin

Targets

VDR (Vitamin D receptor)MTNR1B (Melatonin Receptor 2)MTNR1A (MT1)

Beyond the preview

Go deeper on Mynosit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mynosit.

Explore the full profile